CPHI Milan 2024
【Press Release】
Zhejiang Hengkang Pharmaceuticals invites global customers to join the CPHI exhibition, which is about to open, and innovative products will be unveiled
Hangzhou, China – In the booming global pharmaceutical and health industry, Zhejiang Hengkang Pharmaceuticals Co., Ltd. (hereinafter referred to as “Hengkang Pharmaceuticals”) is honored to announce that it will bring a number of cutting-edge innovative products to the CPHI Milan 2024 which will be grandly opened on Otc 8th. As a well-known provider of pharmaceutical and health solutions in the industry, Hengkang Pharmaceuticals sincerely invites global customers, partners and industry elites to attend the exhibition, join in the celebration, explore new opportunities for cooperation, and jointly draw a blueprint for a healthy future.
Exhibition highlights: New product launches, leading the industry trend
At this exhibition, Hengkang Pharmaceutical will launch four innovative products: PQQ (pyrroloquinoline quinone), SAMe (S-adenosylmethionine), SNAC (N-acetylcysteine) and Mirabegron. These products not only represent Hengkang Pharmaceutical’s deep accumulation and latest research results in the field of biomedicine, but also reflect the company’s unremitting pursuit of improving human health.
PQQ (pyrroloquinoline quinone): As a new type of bioactive substance, PQQ has shown excellent efficacy in anti-oxidation, promoting energy metabolism and neuroprotection, bringing new hope to anti-aging, cardiovascular disease prevention and treatment and other fields.
SAMe (S-adenosylmethionine, S-Adenosyl-L-methionine Disulfate Tosylate): As an important methylation donor in the body, SAMe has significant effects in improving mood, relieving arthritis pain and promoting liver health. It is a star ingredient in the functional health care product market.
SNAC (Salcaprozate Sodium): As a powerful antioxidant and expectorant, SNAC has broad application prospects in the treatment of respiratory diseases, anti-oxidative stress and lung health protection.
Mirabegron: As a new generation of β3 adrenergic receptor agonists, Mirabegron has demonstrated excellent efficacy and safety in the treatment of overactive bladder (OAB), providing patients with a more convenient and effective treatment option.
Inviting global customers to work together for a new chapter of cooperation
Hengkang Pharmaceutical has always adhered to the corporate philosophy of “innovation, quality and service” and is committed to providing high-quality products and solutions to global customers. During the CPHI exhibition, we will not only display these innovative products, but also hold a series of exchange activities, including new product launches, technical seminars and one-on-one business negotiations, aiming to build an efficient and open communication platform for participants to promote information sharing and in-depth cooperation.
About Zhejiang Hengkang Pharmaceutical Co., Ltd.
Zhejiang Hengkang Pharmaceutical Co., Ltd., located in the beautiful Hangzhou, is a comprehensive pharmaceutical company integrating R&D, production and sales. The company has a high-quality R&D team and advanced production equipment, focusing on the R&D and production of biopharmaceuticals, health foods and functional raw materials. Its products are sold at home and abroad and are well received by the market.
Exhibition Information
Exhibition Name: [CPHI Milan 2024 Exhibition]
Holding Time: [Otc 8th to Otc 10th]
Holding Location: [Fiera Milano, Italy]
Booth Number: [3B118]
We sincerely invite you to visit! Let us meet at the CPHI exhibition to witness the innovative achievements of Hengkang Pharmaceutical and work together to create a bright future for the pharmaceutical and health industry!
Contact Information:
Telephone: [+86 -18868723926]
Email: [bd1@hengkangpharm.cn]
Official Website: [https://en.hengkangpharm.cn]
Stay tuned, see you there!